These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 9669287

  • 1. An elevation of stem cell factor in patients with hyperthyroid Graves' disease.
    Yamada T, Sato A, Aizawa T, Ootsuka H, Miyahara Y, Sakai H, Terao A, Onuma S, Ito Y, Kanamori A, Nakamura Y, Tejima E.
    Thyroid; 1998 Jun; 8(6):499-504. PubMed ID: 9669287
    [Abstract] [Full Text] [Related]

  • 2. Thyroid hormone modulates insulin-like growth factor-I(IGF-I) and IGF-binding protein-3, without mediation by growth hormone, in patients with autoimmune thyroid diseases.
    Inukai T, Takanashi K, Takebayashi K, Fujiwara Y, Tayama K, Takemura Y.
    Horm Metab Res; 1999 Oct; 31(10):576-9. PubMed ID: 10596968
    [Abstract] [Full Text] [Related]

  • 3. A possible role of immunoglobulin E in patients with hyperthyroid Graves' disease.
    Sato A, Takemura Y, Yamada T, Ohtsuka H, Sakai H, Miyahara Y, Aizawa T, Terao A, Onuma S, Junen K, Kanamori A, Nakamura Y, Tejima E, Ito Y, Kamijo K.
    J Clin Endocrinol Metab; 1999 Oct; 84(10):3602-5. PubMed ID: 10523002
    [Abstract] [Full Text] [Related]

  • 4. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T, Sato A, Komiya I, Nishimori T, Ito Y, Terao A, Eto S, Tanaka Y.
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [Abstract] [Full Text] [Related]

  • 5. Effect of thyrotropin-releasing hormone on serum thyroid hormones: a study in the patients with untreated and treated Graves' disease and subacute thyroiditis.
    Sato A, Yamada T, Aizawa T, Ichikawa K, Komiya I, Takasu N, Takemura Y.
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2173-7. PubMed ID: 7608274
    [Abstract] [Full Text] [Related]

  • 6. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
    Zwirska-Korczala K, Berdowska A, Jochem J, Sitkiewicz A, Birkner E, Polaniak R, Jedrzejowska-Szypułka H, Korzonek-Szlacheta I.
    J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
    [Abstract] [Full Text] [Related]

  • 7. Increased levels of serum interleukin-18 in Graves' disease.
    Miyauchi S, Matsuura B, Onji M.
    Thyroid; 2000 Sep; 10(9):815-9. PubMed ID: 11041460
    [Abstract] [Full Text] [Related]

  • 8. Natural killer cell activity in patients with Graves' disease and Hashimoto's thyroiditis.
    Wenzel BE, Chow A, Baur R, Schleusener H, Wall JR.
    Thyroid; 1998 Nov; 8(11):1019-22. PubMed ID: 9848716
    [Abstract] [Full Text] [Related]

  • 9. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M, Koizumi Y, Aizawa T, Yamada T, Takahashi Y, Watanabe T, Kamoi K.
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [Abstract] [Full Text] [Related]

  • 10. Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease.
    Yamada T, Komiya I, Miyahara Y, Komatsu M, Shima I, Inazawa T, Aizawa T.
    Endocr J; 2006 Dec; 53(6):783-8. PubMed ID: 16983180
    [Abstract] [Full Text] [Related]

  • 11. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
    Roti E, Minelli R, Gardini E, Bianconi L, Salvi M, Gavaruzzi G, Ugolotti G, Braverman LE.
    J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
    [Abstract] [Full Text] [Related]

  • 12. Significance of thyroid blood flow as a predictor of methimazole sensitivity in untreated hyperthyroid patients with Graves' disease.
    Nagasaki T, Inaba M, Kumeda Y, Fujiwara-Ueda M, Hiura Y, Nishizawa Y.
    Biomed Pharmacother; 2007 Sep; 61(8):472-6. PubMed ID: 17420111
    [Abstract] [Full Text] [Related]

  • 13. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ, Lee BW, Kim JY, Jung JH, Min YK, Lee MS, Lee MK, Kim KW, Chung JH.
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [Abstract] [Full Text] [Related]

  • 14. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
    Aizawa T, Ishihara M, Koizumi Y, Hashizume K, Takasu N, Yamada T, Kobayashi I, Watanabe T, Shimizu Z.
    Am J Med; 1990 Aug; 89(2):175-80. PubMed ID: 2166430
    [Abstract] [Full Text] [Related]

  • 15. Serum concentrations of osteocalcin in patients with hyperthyroidism, hypothyroidism and subacute thyroiditis.
    Kojima N, Sakata S, Nakamura S, Nagai K, Takuno H, Ogawa T, Matsui I, Sarui H, Miura K.
    J Endocrinol Invest; 1992 Aug; 15(7):491-6. PubMed ID: 1447487
    [Abstract] [Full Text] [Related]

  • 16. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M.
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [Abstract] [Full Text] [Related]

  • 17. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
    Takasu N, Kamijo K, Sato Y, Yoshimura H, Nagata A, Ochi Y.
    Clin Exp Pharmacol Physiol; 2004 Feb; 31(5-6):314-9. PubMed ID: 15191404
    [Abstract] [Full Text] [Related]

  • 18. Decrease of immunoglobulin G-Fc receptor-bearing T lymphocytes in Graves' disease.
    Mori H, Amino N, Iwatani Y, Asari S, Izumiguchi Y, Kumahara Y, Miyai K.
    J Clin Endocrinol Metab; 1982 Sep; 55(3):399-402. PubMed ID: 6178751
    [Abstract] [Full Text] [Related]

  • 19. Graves' disease and Hashimoto's thyroiditis: effects of high doses of antithyroid drugs on thyroid autoantibody levels.
    Romaldini JH, Werner MC, Rodrigues HF, Teixeira VL, Werner RS, Farah CS, Bromberg N.
    J Endocrinol Invest; 1986 Jun; 9(3):233-8. PubMed ID: 2428860
    [Abstract] [Full Text] [Related]

  • 20. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P.
    Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.